Literature DB >> 23254954

A new rat model of bone cancer pain produced by rat breast cancer cells implantation of the shaft of femur at the third trochanter level.

Qi Gui1, Chengcheng Xu, Liang Zhuang, Shu Xia, Yu Chen, Ping Peng, Shiying Yu.   

Abstract

Bone cancer pain remains one of the most challenging cancer pains to fully control. In order to clarify bone cancer pain mechanisms and examine treatments, animal models mimicking the human condition are required. In our model of Walker 256 tumor cells implantation of the shaft of femur at the third trochanter level, the anatomical structure is relatively simple and the drilled hole is vertical and in the cortical bone only 1-2 mm in depth without injury of the distal femur. Pain behaviors and tumor growth were observed for 21 days. And neurochemical changes were further investigated in this model. The results showed that cancer-bearing rats demonstrated a decreased limb use score from day 14, an increased spontaneous flinching and guarding times from day 7 and a decreased withdrawal threshold from day 6. The tumor infiltration of bone was monitored by MRI and further verified by histological examination. C-fos and the capsaicin receptor (TRPV1) positive neurons were more expressed in cancer-bearing rats and the substance P expression has no difference, suggesting that neurons were activated in the model. Our animal model demonstrated time-dependent tumor growth and pain behaviors and will be a novel animal model of bone cancer pain in the future.

Entities:  

Keywords:  Walker 256 cell; bone metastases; cancer pain; rat model; the third trochanter

Mesh:

Substances:

Year:  2012        PMID: 23254954      PMCID: PMC3572001          DOI: 10.4161/cbt.23291

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  38 in total

1.  Supraspinal injection of Substance P attenuates allodynia and hyperalgesia in a rat model of inflammatory pain.

Authors:  Carmela Parenti; Giuseppina Aricò; Giuseppe Ronsisvalle; Giovanna M Scoto
Journal:  Peptides       Date:  2012-01-28       Impact factor: 3.750

2.  Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain.

Authors:  Christopher M Peters; Joseph R Ghilardi; Cathy P Keyser; Kazufumi Kubota; Theodore H Lindsay; Nancy M Luger; David B Mach; Matthew J Schwei; Molly A Sevcik; Patrick W Mantyh
Journal:  Exp Neurol       Date:  2005-05       Impact factor: 5.330

3.  Flash freezing of Mohs micrographic surgery tissue can minimize freeze artifact and speed slide preparation.

Authors:  Quenby L Erickson; Trishina Clark; Kassandra Larson; T Minsue Chen
Journal:  Dermatol Surg       Date:  2011-04       Impact factor: 3.398

4.  Induction of c-fos-like protein in spinal cord neurons following sensory stimulation.

Authors:  S P Hunt; A Pini; G Evan
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

5.  Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis.

Authors:  Molly A Sevcik; Nancy M Luger; David B Mach; Mary Ann C Sabino; Christopher M Peters; Joseph R Ghilardi; Matthew J Schwei; Heidi Röhrich; Carmen De Felipe; Michael A Kuskowski; Patrick W Mantyh
Journal:  Pain       Date:  2004-09       Impact factor: 6.961

Review 6.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

7.  Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.

Authors:  Prisca Honore; Prasant Chandran; Gricelda Hernandez; Donna M Gauvin; Joseph P Mikusa; Chengmin Zhong; Shailen K Joshi; Joseph R Ghilardi; Molly A Sevcik; Ryan M Fryer; Jason A Segreti; Patricia N Banfor; Kennan Marsh; Torben Neelands; Erol Bayburt; Jerome F Daanen; Arthur Gomtsyan; Chih-Hung Lee; Michael E Kort; Regina M Reilly; Carol S Surowy; Philip R Kym; Patrick W Mantyh; James P Sullivan; Michael F Jarvis; Connie R Faltynek
Journal:  Pain       Date:  2009-01-09       Impact factor: 6.961

8.  Bone cancer pain.

Authors:  Denis R Clohisy; Patrick W Mantyh
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

9.  Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation.

Authors:  R-X Zhang; B Liu; A Li; L Wang; K Ren; J-T Qiao; B M Berman; L Lao
Journal:  Neuroscience       Date:  2008-05-07       Impact factor: 3.590

10.  Bone cancers.

Authors:  H D Dorfman; B Czerniak
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

View more
  5 in total

1.  Fufang Kushen injection inhibits sarcoma growth and tumor-induced hyperalgesia via TRPV1 signaling pathways.

Authors:  Zhizheng Zhao; Huiting Fan; Tim Higgins; Jia Qi; Diana Haines; Anna Trivett; Joost J Oppenheim; Hou Wei; Jie Li; Hongsheng Lin; O M Zack Howard
Journal:  Cancer Lett       Date:  2014-09-19       Impact factor: 8.679

Review 2.  Using animal models to understand cancer pain in humans.

Authors:  Gillian L Currie; Emily S Sena; Marie T Fallon; Malcolm R Macleod; Lesley A Colvin
Journal:  Curr Pain Headache Rep       Date:  2014-06

3.  Anti-rheumatic drug iguratimod protects against cancer-induced bone pain and bone destruction in a rat model.

Authors:  Yue Sun; Ying-Xing Wu; Peng Zhang; Guang Peng; Shi-Ying Yu
Journal:  Oncol Lett       Date:  2017-04-19       Impact factor: 2.967

Review 4.  The Walker 256 Breast Cancer Cell- Induced Bone Pain Model in Rats.

Authors:  Priyank A Shenoy; Andy Kuo; Irina Vetter; Maree T Smith
Journal:  Front Pharmacol       Date:  2016-08-31       Impact factor: 5.810

5.  The spinal microglial IL-10/β-endorphin pathway accounts for cinobufagin-induced mechanical antiallodynia in bone cancer pain following activation of α7-nicotinic acetylcholine receptors.

Authors:  Evhy Apryani; Usman Ali; Zi-Ying Wang; Hai-Yun Wu; Xiao-Fang Mao; Khalil Ali Ahmad; Xin-Yan Li; Yong-Xiang Wang
Journal:  J Neuroinflammation       Date:  2020-02-29       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.